Taylor Valdetero
Family · Crowley, LANPI 1407252315
Payments from drug & device makers
Across 214 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$931
- Lilly USA, LLC$391
- Novo Nordisk$277
- Abbott$199
- AstraZeneca$190
- Boehringer Ingelheim$190
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,650100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $931 |
| Lilly USA, LLC | 22 | $391 |
| Novo Nordisk | 17 | $277 |
| Abbott | 10 | $199 |
| AstraZeneca | 11 | $190 |
| Boehringer Ingelheim | 12 | $190 |
| Ironwood Pharmaceuticals, Inc | 12 | $165 |
| Amgen | 7 | $118 |
| Astellas Pharma US Inc | 7 | $114 |
| Merck | 5 | $108 |
| Esperion Therapeutics, Inc. | 6 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| Sanofi-aventis U.S. LLC | 6 | $86 |
| Exact Sciences | 4 | $77 |
| Tolmar, Inc. | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| GSK | 2 | $39 |
| Antares Pharma, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Corcept Therapeutics | 1 | $27 |
| Pfizer | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Biogen | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
How this compares
$3,650 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 61 | $77,648 |
| XifaxanRifaximin | 13 | $37,563 |
| JardianceEmpagliflozin | 36 | $28,830 |
| TrulicityDulaglutide | 24 | $24,923 |
| FarxigaDapagliflozin Propanediol | 29 | $20,243 |
| RybelsusSemaglutide | 15 | $16,196 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $13,303 |
| XareltoRivaroxaban | 11 | $11,592 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,522 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,813 |
| JanuviaSitagliptin Phosphate | 13 | $9,069 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,263 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,246 |
| Liothyronine Sodium | 242 | $6,203 |
| Insulin Aspart FlexpenInsulin Aspart | 19 | $2,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $391 | $102,57185 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $92 | $37,56313 claims |
| Boehringer IngelheimJardiance | $190 | $28,83036 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $39 | $21,33430 claims |
| AstraZenecaFarxiga | $190 | $20,24329 claims |
| Novo NordiskRybelsus | $277 | $16,19615 claims |
| Johnson & JohnsonXarelto | $33 | $11,59211 claims |
| MerckJanuvia | $108 | $9,06913 claims |
| AbbVieNamzaric, Synthroid | $931 | $8,45524 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $104 | $6,24613 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $14 | $2,07480 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Crowley
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.